A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting

被引：0
|
作者：
Laura McCullagh
Lesley Tilson
Cathal Walsh
Michael Barry
机构：
[1] St James’s Hospital,National Centre for Pharmacoeconomics
[2] Trinity College Dublin,Department of Statistics
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Deep Venous Thrombosis; Dabigatran; Rivaroxaban; Total Knee Replacement; Probabilistic Sensitivity Analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: It has been estimated that major orthopaedic surgery has the highest risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) when compared with other surgery. Two new orally active anticoagulants have recently become licensed in Ireland for the primary prevention of venous thromboembolism in adult patients undergoing elective total hip replacement (THR) or total knee replacement (TKR). Rivaroxaban (Xarelto®) is a direct factor Xa inhibitor and dabigatran etexilate (Pradaxa®) is a prodrug of the active compound dabigatran, which inhibits thrombin.
引用
收藏
页码：829 / 846
页数：17
相关论文
共 50 条
  • [1] A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
    McCullagh, Laura
    Tilson, Lesley
    Walsh, Cathal
    Barry, Michael
    PHARMACOECONOMICS, 2009, 27 (10) : 829 - 846
  • [2] A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting
    Zindel, Sonja
    Stock, Stephanie
    Mueller, Dirk
    Stollenwerk, Bjoern
    BMC HEALTH SERVICES RESEARCH, 2012, 12
  • [3] A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting
    Sonja Zindel
    Stephanie Stock
    Dirk Müller
    Björn Stollenwerk
    BMC Health Services Research, 12
  • [4] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT OR TOTAL KNEE REPLACEMENT IN COLOMBIA
    Pereira, R.
    Duran, A.
    Lindner, L.
    Toro, W.
    Arango, C. H.
    VALUE IN HEALTH, 2009, 12 (07) : A502 - A502
  • [5] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN SPAIN
    Diamantopoulos, A.
    Forster, F.
    Brosa, M.
    Lees, M.
    Pinol, C.
    Febrer, L.
    VALUE IN HEALTH, 2008, 11 (06) : A533 - A533
  • [6] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PROPHYLAXIS AFTER TOTAL HIP OR TOTAL KNEE REPLACEMENT IN KOREA
    Kim, J.
    Pollock, R.
    Jung, S.
    Diamantopoulos, A.
    Lees, M.
    VALUE IN HEALTH, 2009, 12 (03) : A147 - A148
  • [7] Enoxaparin vs. dabigatran etexilate or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty
    Huisman, M., V
    Quinlan, D. J.
    Dahl, O. E.
    Schulman, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1070 - 1070
  • [8] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
    Vorobyev, P.
    Krasnova, L.
    Borisenko, O.
    Lukyantseva, D.
    Bashlakova, E.
    VALUE IN HEALTH, 2011, 14 (03) : A40 - A40
  • [9] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT
    Vorobyev, P.
    Krasnova, L.
    Borisenko, O.
    Lukyantseva, D.
    Bashlakova, L.
    VALUE IN HEALTH, 2011, 14 (03) : A41 - A41
  • [10] Cost-Effectiveness of Rivaroxaban After Total Hip or Total Knee Arthroplasty
    Kwong, Louis M.
    AMERICAN JOURNAL OF MANAGED CARE, 2011, 17 (01): : S22 - S26
12345